Some studies have found that targeting CDK4/CDK6 can treat gastric cancer, and the main mechanism by which this approach exerts its effects is by impeding the cell cycle’s progression from the G1 phase to the S phase, thereby curbing the expansion and proliferation of malignant cells [29]. Here, CDK6 is linked to gastric cancer.